Umibe5690,
Where DCVax-L appears to work best for most patients in the transition period from genotype to phenotype. There are essentially 4 original genotypes plus sub categories. Some sub categories appear to have distinct positive or negative chacteristics based on type of treatment received. In general, though, up to 85% of all original genotypes end up being a mesenchymal phenotype at transition and this is where exposed antigen targets can be hit by DCVax-L therapy intervention which causes increased immune surveillance as well as specific antigen recognition by T-cells and others. This usually either slightly slows down the process of tumor reestablishment or cripples it really well in some cases. Methylation helps slow down initial repair and recovery and a higher percentage of proneural are methylated which is one reason why proneural patients tend to live longer on standard care. Younger patients also tend to be proneural and I believe the impact of higher levels of certain growth factors and hormones in younger patients probably play a part. There are degrees of methylation and various studies have been done to see how this impacts patients. Women also respond to various treatments and methylation status differently than men. We will all learn more but there are some methylated mesenchymal patients that did very well in Phase 1. Best wishes.
News 
Market Data 
Discover 
